Google Cloud's revenue grew 30% YoY in Q4'24 with margins up to 17.51%, driven by AI advancements. Discover their $75B ...

Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...

Vertex stock today trades for about 24x forward earnings estimates. This is higher than in recent weeks but still very reasonable, considering Vertex's solid CF business and this new opportunity ...

“Now four weeks into the mission, Blue Ghost has downlinked more than 15 GB of data, including NASA science data, from record-breaking GNSS signals to magnetic field measurements, that is already ...

Vertex Pharmaceuticals stock declined almost 13% in six months due to poor test results for a new drug. When it comes to the drug and biotech sector, a major pipeline setback can hit the stock hard.

JOSEPH PREZIOSO / AFP via Getty Images Vertex Pharmaceuticals' non-opioid painkiller received approval from the Food and Drug Administration. The drugmaker said the twice-daily pill, Journavx ...

it's worth examining whether Vertex stock remains a compelling buy right now. Image source: Getty Images. Vertex has built an empire in cystic fibrosis (CF) treatment, recently crowning its ...

Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved the company’s non-opioid pain treatment. It’s the first new class ...

At 23.8 times forward earnings, Vertex stock trades in line with the broader S&P 500 index, which is at 23.6 times earnings -- a surprising valuation for a company with a dominant market share and ...

Vertex stock trades at 23.8 times forward earnings (in line with the S&P 500), with $11.2 billion in cash and strong growth prospects. The healthcare sector has struggled to deliver worthwhile ...